Nasdaq · CIK 0001649989
OTLK Outlook Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 41 d ago.
Outlook Therapeutics, Inc. (OTLK) has 16 SEC Form 4 filings on file from 11 insiders, the latest filed on Sep 2, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 open-market trades have been scored at OTLK. The newest: Yezan Munther Haddadin (director) bought $24k of stock on Jun 2, 2026, filed Jun 3, 2026, scored 45 (moderate). The largest of the 4 shown: Ghiath M. Sukhtian (director and 10% owner) bought $5.0M on May 28, 2026, scored 65 (notable). 3 insiders bought within 14 days of each other around Jun 2, 2026.
Last 90 days
Signals
Open-market buys and sells at Outlook Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Yezan Munther Haddadin director buy | $24k 29,000 shares | +78% | - | |
| 65Notable | Ghiath M. Sukhtian director, owner buy | $5.0M 8,539,709 shares | +63% | - | |
| 52Moderate | Kurt J Hilzinger director buy | $177k 400,000 shares | +1691% | - | |
| 40Moderate | Yezan Munther Haddadin director buy | $15k 34,000 shares | +1074% | - |
Transactions
Every row filed, 33 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Kevin Michael Lundquist Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +500,000 | $0.00 | $0 | 500,000 | 41 d ago |
| Jun 2, 2026 | Yezan Munther Haddadin director | POpen-market purchase Common Stock | +29,000 | $0.83 | $24k | 66,167 | Jun 3, 2026 |
| May 28, 2026 | Ghiath M. Sukhtian director, owner | POpen-market purchase Common Stockindirect: See footnote | +8,539,709 | $0.59 | $5.0M | 22,092,068 | Jun 1, 2026 |
| May 28, 2026 | Ghiath M. Sukhtian director, owner | HExpiration of long derivative Warrants (right to buy)derivativeindirect: See footnote | -3,458,571 | - | - | 0 | Jun 1, 2026 |
| May 28, 2026 | Ghiath M. Sukhtian director, owner | POpen-market purchase Warrants (right to buy)derivativeindirect: See footnote | +3,458,571 | - | - | 3,458,571 | Jun 1, 2026 |
| May 28, 2026 | Ghiath M. Sukhtian director, owner | HExpiration of long derivative Warrants (right to buy)derivativeindirect: See footnote | -3,458,571 | - | - | 0 | Jun 1, 2026 |
| May 28, 2026 | Ghiath M. Sukhtian director, owner | POpen-market purchase Warrants (right to buy)derivativeindirect: See footnote | +3,458,571 | - | - | 3,458,571 | Jun 1, 2026 |
| May 28, 2026 | Ghiath M. Sukhtian director, owner | HExpiration of long derivative Warrants (right to buy)derivativeindirect: See footnote | -8,571,428 | - | - | 0 | Jun 1, 2026 |
| May 28, 2026 | Ghiath M. Sukhtian director, owner | POpen-market purchase Warrants (right to buy)derivativeindirect: See footnote | +8,571,428 | - | - | 8,571,428 | Jun 1, 2026 |
| May 26, 2026 | Yezan Munther Haddadin director | POpen-market purchase Common Stock | +34,000 | $0.44 | $15k | 37,167 | May 27, 2026 |
| May 26, 2026 | Kurt J Hilzinger director | POpen-market purchase Common Stock | +400,000 | $0.44 | $177k | 423,655 | May 27, 2026 |
| Oct 1, 2025 | Randy H Thurman director | AGrant or award Stock Option (Right to Buy)derivative | +286,734 | $0.00 | $0 | 286,734 | Oct 3, 2025 |
| Oct 1, 2025 | Faisal Ghiath Sukhtian director | AGrant or award Stock Option (Right to Buy)derivative | +286,734 | $0.00 | $0 | 286,734 | Oct 3, 2025 |
| Oct 1, 2025 | Andong Huang director | AGrant or award Stock Option (Right to Buy)derivative | +286,734 | $0.00 | $0 | 286,734 | Oct 3, 2025 |
| Oct 1, 2025 | Julia A Haller director | AGrant or award Stock Option (Right to Buy)derivative | +286,734 | $0.00 | $0 | 286,734 | Oct 3, 2025 |
| Oct 1, 2025 | Yezan Munther Haddadin director | AGrant or award Stock Option (Right to Buy)derivative | +286,734 | $0.00 | $0 | 286,734 | Oct 3, 2025 |
| Oct 1, 2025 | Gerd Auffarth director | AGrant or award Stock Option (Right to Buy)derivative | +286,734 | $0.00 | $0 | 286,734 | Oct 3, 2025 |
| Oct 1, 2025 | Julian S Gangolli director | AGrant or award Stock Option (Right to Buy)derivative | +286,734 | $0.00 | $0 | 286,734 | Oct 3, 2025 |
| Oct 1, 2025 | Kurt J Hilzinger director | AGrant or award Stock Option (Right to Buy)derivative | +286,734 | $0.00 | $0 | 286,734 | Oct 3, 2025 |
| Oct 3, 2025 | Faisal Ghiath Sukhtian director | AGrant or award Stock Option (Right to Buy)derivative | +117,296 | $0.00 | $0 | 117,296 | Oct 3, 2025 |
| Oct 3, 2025 | Andong Huang director | AGrant or award Stock Option (Right to Buy)derivative | +53,316 | $0.00 | $0 | 53,316 | Oct 3, 2025 |
| Oct 3, 2025 | Julia A Haller director | AGrant or award Stock Option (Right to Buy)derivative | +58,648 | $0.00 | $0 | 58,648 | Oct 3, 2025 |
| Oct 3, 2025 | Yezan Munther Haddadin director | AGrant or award Stock Option (Right to Buy)derivative | +95,969 | $0.00 | $0 | 95,969 | Oct 3, 2025 |
| Oct 3, 2025 | Kurt J Hilzinger director | AGrant or award Stock Option (Right to Buy)derivative | +90,638 | $0.00 | $0 | 90,638 | Oct 3, 2025 |
| Oct 3, 2025 | Gerd Auffarth director | AGrant or award Stock Option (Right to Buy)derivative | +58,648 | $0.00 | $0 | 58,648 | Oct 3, 2025 |
| Jul 1, 2025 | Robert Charles Jahr Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +800,000 | $0.00 | $0 | 800,000 | Jul 9, 2025 |
| May 27, 2025 | Ghiath M. Sukhtian director, owner | AGrant or award Common Stockindirect: See footnote | +4,285,714 | $1.40 | $6.0M | 13,552,359 | May 28, 2025 |
| May 27, 2025 | Ghiath M. Sukhtian director, owner | AGrant or award Warrants (right to buy)derivativeindirect: See footnote | +8,571,428 | - | - | 8,571,428 | May 28, 2025 |
| Jan 17, 2025 | Ghiath M. Sukhtian director, owner | DDisposition to issuer Warrants (right to buy)derivativeindirect: See footnote | -3,458,571 | - | - | 0 | Jan 22, 2025 |
| Jan 17, 2025 | Ghiath M. Sukhtian director, owner | AGrant or award Warrants (right to buy)derivativeindirect: See footnote | +3,458,571 | - | - | 3,458,571 | Jan 22, 2025 |
| Jan 17, 2025 | Ghiath M. Sukhtian director, owner | MOption exercise Warrants (right to buy)derivativeindirect: See footnote | -3,458,571 | - | - | 0 | Jan 22, 2025 |
| Jan 17, 2025 | Ghiath M. Sukhtian director, owner | AGrant or award Warrants (right to buy)derivativeindirect: See footnote | +3,458,571 | - | - | 3,458,571 | Jan 22, 2025 |
| Jan 17, 2025 | Ghiath M. Sukhtian director, owner | AGrant or award Warrants (right to buy)derivativeindirect: See footnote | +3,458,571 | - | - | 3,458,571 | Jan 22, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Gerd Auffarthdirector
- Julian S Gangollidirector
- Kurt J Hilzingerdirector
- Yezan Munther Haddadindirector
- Julia A Hallerdirector
- Andong Huangdirector
- Robert Charles JahrChief Executive Officer
- Kevin Michael LundquistChief Financial Officer
- Faisal Ghiath Sukhtiandirector
- Ghiath M. Sukhtiandirector, owner
- Randy H Thurmandirector
Questions about OTLK
Answered from the filings on this page, as of the latest one.
Are insiders buying OTLK?
No. In the last 90 days no insider at Outlook Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade OTLK on the open market?
Yezan Munther Haddadin (director) bought $24k of OTLK on Jun 2, 2026 and filed the Form 4 on Jun 3, 2026. InsiderTell scored 45 (moderate), with 3 insiders on the same side within 14 days.
How many insiders file Form 4 at Outlook Therapeutics, Inc.?
11 people have filed a Form 4 at Outlook Therapeutics, Inc., among them Gerd Auffarth (director), Julian S Gangolli (director), Kurt J Hilzinger (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.